Botulinum Toxin for Mentum and Perioral Area

  • Maria Del Pilar Del Rio Navarrete BiotEmail author
Living reference work entry

Latest version View entry history

Part of the Clinical Approaches and Procedures in Cosmetic Dermatology book series (CAPCD)


There is no doubt that the treatment with botulinum toxin is the most popular aesthetic procedure for facial rejuvenation. At the beginning, it was indicated only for the upper face, but now, it is frequently injected for the treatment of the lower face. When treating this area, the goal is to relax the muscles. In the perioral area, the muscle to be treated is the orbicularis oris, important for the execution of simple actions like speaking, drinking, and blowing, and which impairment would be very unpleasant. This is especially important for those who need a total competence of the lips in their jobs, like speakers, musicians, scuba divers, and others. A complete knowledge of the anatomy and the correct injection technique, not exceeding the total number of units recommended, are essential for a safe and successful treatment of the lower face. The anatomy is important not only for the perioral area treatment but also for the mentum, because of the proximity and numerous muscle intersections at this region. For example, when treating the mentum, it is possible to accidentally relax the orbicularis oris. We hope that with this chapter, we contribute for a better understanding of the lower face treatment and that after reading it, the injector feels confident to inject this region.


Dynamic lines Botulinum toxin Paralysis Lower face Bar code Perioral Upper lip Lower lip Vermilion Columella Mentum Orbicularis oris Levator anguli oris Depressor anguli oris Depressor labii inferioris Dimpled chin 


  1. Ascher B, Talarico S, Cassuto D, Escobar S, Hexsel D, Jaén P, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood unit) – part II: wrinkles on the middle and lower face, neck and chest. J Euro Acad Dermatol Venereol. 2010;24(11):1285–95.CrossRefGoogle Scholar
  2. Carruthers J, Carruthers A. Aesthetic botulinum A toxin in the mid and lower face and neck. Dermatol Surg. 2003;29(5):468–76.PubMedPubMedCentralGoogle Scholar
  3. Carruthers A, Carruthers J, Monheit GD, Davis PG, Tardie G. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxin and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatol Surg. 2010;36(Suppl 4):2121–34.CrossRefGoogle Scholar
  4. Cohen JL, Dayan SH, Cox SE, Yalamanchili R, Tardie G. Onabotulinumtoxin A dose ranging study for hyper dynamic perioral lines. Dermatol Surg. 2012;38(9):1497–505.CrossRefGoogle Scholar
  5. Gassia V, Raspaldo H, Niforos FR, Michaud T. Global 3 – dimensional approach to natural rejuvenation: recommendations for perioral, nose, and ear rejuvenation. J Cosmet Dermatol. 2013;12(2):123–36.CrossRefGoogle Scholar
  6. Gray’s Anatomia: a base anatômica da pratica clínica. 40a edição. Elsevier Editora; 2015.Google Scholar
  7. Hexsel D, Brum C, Porto MD, Soirefmann M, Siega C, Schilling-Souza J, et al. Full-face injections of variable total doses of abobotulinum toxin type A: a randomized phase IV clinical trial of safety and efficacy. J Drugs Dermatol. 2013;12(12):1356–62.PubMedGoogle Scholar
  8. Mandy S. Art of the lip. Dermatol Surg. 2007;33:521–2.PubMedGoogle Scholar
  9. Pena MA, Alam M, Yoo SS. Complications with the use of botulinum toxin type A for cosmetic applications and hyperhidrosis. Semin Cutan Med Surg. 2007;26(1):29–33.CrossRefGoogle Scholar
  10. Raspaldo H, Niforos FR, Gassia V, Dallara JM, Bellity P, Bellaouari L, et al. Lower -face and neck antiaging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus – part 2. J Cosmet Dermatol. 2011;10(2):131–49.CrossRefGoogle Scholar
  11. Semchyshyn N, Sengelmann RD. Botulinum toxin A treatment of perioral rhytids. Dermatol Surg. 2003;29(5):490–5.PubMedGoogle Scholar
  12. Shetty MK, Dermatosurgery Task Force. Guidelines on the use of botulinum toxin type A. Indian J Dermatol Venereol. 2008;74(Suppl:S13–22)Google Scholar
  13. Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A. Am J Clin Dermatol. 2005;6(3):141–50.CrossRefGoogle Scholar
  14. Yutskovskaya Y, Gubanova E, Khrustaleva I, Atamanov V, Saybel A, Parsagashvili E, et al. IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations. Clin Cosmet Investig Dermatol. 2015;8:297–306.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Clinica dermatológica maria del pilar biotNiteróiBrazil

Personalised recommendations